<DOC>
	<DOCNO>NCT00311818</DOCNO>
	<brief_summary>Primary objective : - To compare efficacy oral antidiabetic ( OAD ) combination therapy either HOE901 insulin analogue daily Lispro insulin analogue mealtime term change HbA1c ( baseline endpoint ) . Secondary objective : - To compare OAD combination therapy either HOE901 insulin analogue daily Lispro insulin analogue mealtime term efficacy safety .</brief_summary>
	<brief_title>Insulin Glargine Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Subjects Type 2 Diabetes mellitus least 1 year ( history ketoacidosis ) treatment oral antidiabetic ( OAD ) least 6 month prior study entry Subjects poorly control previous OAD treatment : mono combination therapy approve combination insulin accord local SPCs ( summary product characteristic ) , include use alphaglucosidase inhibitor , stable dose least 3 month prior study entry Poor metabolic control HbA1c ( glycosylated hemoglobin ) value 7.5 % 10.5 % FBG &gt; = 120 mg/dl ( 6.6 mmol/l ) Body mass index &lt; = 35 kg/m2 Ability willingness tight antidiabetic therapy stable lifestyle regular meal perform blood glucose self monitoring especially blood glucose profile use blood glucose meter home , evidence daily FBG measurement complete 8point blood glucose profile obtain 24hour period Treatment insulin last 4 week prior study entry Diabetes mellitus follow pancreatectomy GAD positive ( glutamic acid decarboxylase ) Diabetic retinopathy surgical treatment ( laser photocoagulation vitrectomy ) 3 month prior study entry may require surgical treatment within 3 month study entry Pregnant breastfeed Women childbearing potential take adequate contraceptive protection systemic hormone ( birth control pill , implant ) , intrauterine device , barrier method ( diaphragm intravaginal spermicidal , cervical cap , male female condom ) History hypersensitivity study medication drug similar chemical structure Treatment investigational drug last 3 month study entry Previous enrollment study involve HOE901 insulin analogue Likelihood require treatment study period drug permit study protocol ( e.g . noncardio selective betablockers , systemic corticosteroid ) Clinically relevant cardiovascular , gastrointestinal , hepatic , neurologic , endocrine , hematological major systemic disease make implementation protocol interpretation study result difficult History drug alcohol abuse Impaired hepatic function , show , limited , alanine aminotransferase ( ALAT ) aspartate aminotransferase ( ASAT ) 3x upper limit normal , low value require individually administer OAD Impaired renal function , show , limited , serum creatinine &gt; 177 mmol/l ( &gt; 2 mg/dl ) , low value require individually administer OAD The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>